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Abstract
Cushing’s disease (CD) is the most common cause of endogenous Cushing’s syndrome (CS). The goal of treatment
is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce
long-term complications associated with increased mortality.
While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have traditionally
been seen as second-line therapies for persistent hypercortisolism. Medical therapy is now recognized to play a key
role in the control of cortisol excess. In this review, all currently available medical therapies are summarized, and novel
medical therapies in phase 3 clinical trials, such as osilodrostat and levoketoconazole are discussed, with an emphasis
on indications, efficacy and safety. Emerging data suggests increased efficacy and better tolerability with these novel
therapies and combination treatment strategies, and potentially increases the therapeutic options for treatment of CD.
New insights into the pathophysiology of CD are highlighted, along with potential therapeutic applications.
Future treatments on the horizon such as R-roscovitine, retinoic acid, epidermal growth factor receptor inhibitors
and somatostatin-dopamine chimeric compounds are also described, with a focus on potential clinical utility.
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P450 3A; D2R, Dopamine type 2 receptor; DPP-4, Dipeptidyl peptidase 4; EGFR, Epidermal growth factor receptor;
GABA, Gamma-amino butyric acid; GLP-1, Glucagon-like peptide-1; GR, Glucocorticoid receptor; LAR, Long-acting
repeatable; MC2R, Melanocortin type 2 receptor; MRI, Magnetic resonance imaging; POMC, Proopiomelanocortin;
PPAR-gamma, Peroxisome proliferator-activated receptor gamma; sc, Subcutaneous; SEISMIC, Study of the efficacy
and safety of mifepristone in the treatment of endogenous Cushing’s syndrome; SRL, Somatostatin receptor
ligand; SSTR, Somatostatin receptor; USP8, Ubiquitin specific peptidase eight
Background
In 1932, Harvey Cushing described a syndrome charac-
terized by serious manifestations consequent to systemic
effects of chronic exposure to cortisol “…which has been
found at autopsy in 6 out of 8 to be associated with a
pituitary adenoma…” [1]. Cushing’s syndrome (CS) re-
sults from chronic, excessive exposure to glucocorti-
coids, the source of which may be either exogenous or
endogenous. The most common cause (70 %) of en-
dogenous cortisol production is Cushing’s disease (CD)
due to overproduction of adrenocorticotropic hormone
(ACTH) by a pituitary corticotroph adenoma [2, 3].
ACTH, in turn, stimulates melanocortin type 2 receptor
(MC2R) at the adrenal cortex and increases cortisol syn-
thesis [4, 5]. CD is more frequently observed in women,
and in about 90 % of cases, is due to a pituitary microa-
denoma or corticotroph hyperplasia. Once ACTH-
dependent glucocorticoid excess is confirmed, further
tests are used to clarify the source of ACTH secretion
[2, 6, 7]. Magnetic resonance imaging (MRI) may con-
firm the presence of a pituitary adenoma, however, in up
to 40 % of cases, an adenoma remains undetectable [8,
9]. When a lesion is not visible or appears smaller than
6 mm on imaging, bilateral inferior petrosal sinus sam-
pling is recommended to clearly distinguish between CD
and ectopic ACTH production [6].
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The goals of treating CD are to eliminate the source of
ACTH excess, achieve biochemical eucortisolism and
long-term remission, to reverse clinical features, reduce
long-term complications and mortality, and improve
quality of life [10]. Surgical resection of the identified
pituitary adenoma remains first line treatment in CD
patients, however, remission rates are reported to be
65–90 % for those with microadenomas and less than
65 % for those with macroadenomas [11, 12]. While re-
peat pituitary surgery, pituitary radiotherapy or bilateral
adrenalectomy have traditionally been used as adjuvant
therapies in persistent hypercortisolism [3, 11, 13],
medical treatment now plays an increasingly important
role in CD management [7, 10, 14]. Novel therapeutic
medications and strategies have recently emerged. Such
medications are summarized in this review, with emphasis
placed on indications, efficacy and safety. New medical
treatments on the horizon for CD are described, with a
focus on treatments with potential clinical utility in the
near future.
Indications for medical therapy
Over the last 10 years, the armamentarium of drugs
available for CD treatment has expanded significantly.
Many drugs have been shown to decrease cortisol levels
and improve the clinical syndrome, and a reduction in
tumor volume has been observed with some [15]. Medical
therapy should be considered in the following circum-
stances: 1) as adjuvant therapy for persistent hypercortiso-
lism after surgery [10, 16]; 2) as a pre-operative treatment
in severe cases, [17]; 3) treatment of acute and life-
threatening hypercortisolism complications (i.e. sepsis,
uncontrolled hypertension, severe hyperglycemia, heart
failure, intractable hypokalemia and psychosis [18, 19];
4) whilst awaiting the full treatment effects of radio-
therapy [20]; and 5) as first-line treatment in patients
with surgical contraindications, those who decline surgery,
in whom no definite lesion is seen, or when tumor is in an
unfavorable location [14].
Medical treatments currently used in Cushing’s
disease
Medications currently used in the treatment of CD are
classified according to their mechanism of action as ad-
renal steroidogenesis inhibitors, pituitary-directed drugs
and glucocorticoid receptor antagonists [21] (Table 1).
Adrenal steroidogenesis inhibitors
Adrenal steroidogenesis inhibitors block cortisol synthesis
by inhibiting multiple key enzymes involved in steroido-
genesis. Cortisol levels decrease, but no effect is observed
on the underlying corticotroph tumor. There are no
prospective studies on the efficacy and safety of ste-
roidogenesis inhibitors, and variability in study design
and quality makes comparison of efficacy difficult [22, 23].
Currently, apart from metyrapone and ketoconazole,
which are approved in the European Union (EU), ste-
roidogenesis inhibitors are used as off-label therapy in
most other countries. Cortisol excess may be rapidly con-
trolled but the “escape phenomenon” is common and
higher doses are needed in the long-term to achieve
disease control. They are therefore most commonly
used temporarily as pre-operative treatment in patients
with severe complications from CS when rapid control
is necessary, and as a bridging therapy after radiotherapy
[14, 22, 24]. Two treatment approaches are used:
“normalization” of cortisol and the “block and replace”
strategy that involves complete blockage of cortisol
production and replacement with physiological doses
of glucocorticoids.
Because of their effects on hepatic cytochrome p450
expression, drug interactions are commonly seen with
adrenal steroidogenesis inhibitors. There is also limited
experience with these medications during pregnancy and
as Cushing’s disease affects mostly women of reproductive
age, caution is advised in women planning pregnancy.
Individual drug dosing, frequency and adverse effects are
summarized in Table 1.
Ketoconazole
Ketoconazole is an imidazole derivative first used as
an anti-fungal therapy. It was noted, however, that
patients developed adrenal insufficiency at high doses.
Ketoconazole inhibits steroidogenesis by blocking
cholesterol side-chain cleavage complex, 17,20-lyase,
11beta-hydroxylase and 17 alpha-hydroxylase enzymes
[25]. It has been postulated that ketoconazole also has
an inhibitory effect on corticotroph ACTH secretion,
though this remains debatable [26]. In the largest
retrospective study to date (FReSKO), 200 patients
received ketoconazole at doses of 200–1200 mg daily
for pre-operative, primary and secondary treatment of
CD. At last follow-up (mean 20.6 months), about half
achieved normal urine free cortisol (UFC) levels and
an additional 26 % had a ≥ 50 % decrease, associated
with clinical improvement. Escape from treatment
however, was demonstrated in 23 % of those with
initial response [27]. Of note, like in previous reports,
intolerability resulted in treatment cessation in ap-
proximately one-fifth of patients. Though generally re-
versible upon drug withdrawal, up to 5-fold increases
in liver enzymes were found in 13.5 % of patients
while severe hepatotoxicity (>5-fold elevation) was ob-
served in 2.5 %. It is recommended that liver function
be closely monitored during treatment with ketocona-
zole and dose reduction or discontinuation is advised
when liver enzymes are 3-fold elevated [10]. More
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recently, use of ketoconazole as a combination therapy
has been studied (see below).
Fluconazole
Fluconazole was found in in vitro studies to inhibit cor-
tisol production in human adrenocortical cells via inhib-
ition of 17-hydroxylase and 11-beta hydroxylase. The
effect was shown to be dose-dependent; potency was
lower than ketoconazole. Though potentially promising
and with less risk for hepatotoxicity, there are few re-
ports of fluconazole use demonstrating clinical efficacy
[28, 29].
Metyrapone
This steroidogenesis inhibitor primarily blocks 11-beta
hydroxylase, as well as the cholesterol side chain cleav-
age complex, 17-alpha hydroxylase and 18-hydroxylase
enzyme activities. Studies demonstrate normalization of
cortisol secretion in 45–75 % of patients [17, 30, 31]. In
the largest and most recent multicenter retrospective study
to date, 195 patients with CS (59 % CD) were treated with
metyrapone for a mean duration of 8 months. The majority
was being treated pre-operatively for control of severe CS;
35 patients were on combination therapy. In patients on
monotherapy, 55 %, 46–76 %, and 43 % of patients
achieved biochemical control as assessed by a normal cor-
tisol day curve, morning cortisol and UFC, respectively.
Longer-term data (mean 18 months) available for 38 pa-
tients showed biochemical eucortisolism in 72 % [32].
Overall, escape has been reported in up to 19 % of pa-
tients with an initial response [14]. In addition, ACTH
levels frequently increase and may drive androgen and
mineralocorticoid overproduction, causing multiple adverse
events (Table 1). Mineralocorticoid overproduction occurs
due to 11-beta hydroxylase inhibition and accumulation
of aldosterone precursors. To avoid mineralocorticoid-
related adverse events, metyrapone is therefore often used
in the short-term, for pre-operative control and in severe
CD in combination with ketoconazole [33], though cases
of long-term use have been reported [34].
Table 1 Medical therapy for Cushing’s disease
Classification Drug name Dose Possible adverse events; Close monitoring is necessary for all drugs
Steroidogenesis
inhibitors
Ketoconazole Oral 200–1200 mg/day
2–3 times a day
Hepatitis, gastrointestinal disturbances, gynecomastia, skin rash, adrenal
insufficiency.
Fluconazole Oral 100–200 mg/day
2 times a day
AEs similar to ketoconazole, not well studied
Metyrapone Oral 0.5–6 g/day
4 times a day
Hirsutism, acne, hypertension, hypokalemia, edema, gastritis, nausea,
adrenal insufficiency.
Etomidate IV bolus of 0.03 mg/kg followed by
0.02–0.08 mg/kg/h
Somnolence, myoclonus, nausea, vomiting, dystonic reactions, adrenal
insufficiency.
Mitotane Oral 2–5 g/day
3 times a day
Gastrointestinal disturbances, hepatitis, neurologic manifestations,
gynecomastia, neutropenia, lipid disorders, adrenal insufficiency;
teratogenic
Osilodrostat Oral 10–60 mg/day; phase III clinical
trial: NCT 02180217
Nausea, asthenia, diarrhea, adrenal insufficiency. Testosterone increase in
women.





Cabergoline Oral 0.5–7 mg/week Headache, nausea, dizziness, nasal congestion, hypotension, depression
SRLs Pasireotidea SC 300–1800 µg/day
2 times a day
Hyperglycemia, diabetes, diarrhea, nausea, abdominal pain, cholelithiasis,
QT prolongation
Pasireotide LAR IM 30–60 mg/month; phase III
clinical trial
GR antagonist Mifepristonea Oral 300–1200 mg/day
Once daily
Nausea, fatigue, headache, hypokalemia, arthralgia, vomiting, peripheral
edema, hypertension, dizziness, adrenal insufficiency, PAECs, endometrial
thickening, vaginal bleeding; termination of pregnancy.
CDK2/Cyclin E
inhibitor





Retinoic acid Oral Phase II clinical trial;
clinicaltrialsregister.eu number: 2008-
006379-65
D2R dopamine D2 receptor, SRL somatostatin receptor ligand, SC subcutaneous, IM intramuscular, LAR long-acting repeatable, PAECs- progesterone-receptor
modulator-associated endometrial changes
aFDA approved
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Etomidate
Similar to other adrenal-directed drugs, etomidate acts
by blocking multiple enzymes involved in steroidogene-
sis such as side-chain cleavage complex, 17-hydroxylase,
11 beta-hydroxylase, 17–20 lyase enzymes and aldoster-
one synthase [35]. After intravenous administration, a
rapid and significant suppression of serum cortisol levels
is seen within 5 h and maximal suppression occurs at
11 h [36–39]. Etomidate is therefore used to rapidly con-
trol severe manifestations of CS such as psychotic crises,
severe sepsis or hypertension, in patients who are not
immediate surgical candidates and are unable to tolerate
oral medications [10, 40, 41]. Use of etomidate, however,
should be limited to the intensive care setting, with
close monitoring for central nervous system depression.
Multiple regimens have been studied to block steroido-
genesis whilst trying to avoid its anesthetic effects. Vari-
ous approaches for complete and partial blockade also
exist [40–42]. Guidelines published by the Endocrine Soci-
ety suggest a loading dose followed by a weight-based con-
tinuous infusion titrated to achieve serum cortisol levels
between 10 and 20 μg/dL (280–560 nmol/L) [10]. It has,
however, also been suggested that treatment targets in the
intensive care setting, be higher than in the non-acute set-
ting at 18–30 μg/dL (500–800 nmol/L) [41]. Serum elec-
trolytes and cortisol levels therefore need to be
monitored every 4–6 h, to achieve target cortisol levels
and to prevent adrenal insufficiency, which may require
treatment with intravenous hydrocortisone (“block and
replace” regimen) [14].
Mitotane
Mitotane (o,p’-diphenylmethane derivative agent) has both
adrenostatic and adrenolytic actions, and is for this reason,
most commonly used in the treatment of adrenocortical
carcinoma. Mitotane blocks the cholesterol side-chain
cleavage complex, 11 beta-hydroxylase, 18-hydroxylase
and 3 beta-hydroxysteroid-dehydrogenase (HSD3B2) en-
zymes, reducing cortisol production [43]. Due to its slow
onset of action, efficacy is delayed; therapeutic levels are
achieved in up to 3 months. Remission rates up to 100 %
have been reported, however, concomitant use of pituitary
irradiation is likely to have confounded these results [14].
A single-center French retrospective study of 67 patients
with CD demonstrated remission in 72 % after treatment
for a median duration of 6.7 months. Adverse events were
frequent, including gastrointestinal disturbance (50 %),
impaired mentation and dizziness (30 %) [44]. Mitotane’s
long half-life (up to 160 days) also results in significant
circulating drug levels despite drug continuation [43].
Supraphysiological doses of hydrocortisone replacement
are often necessary to treat adrenal insufficiency as
mitotane increases cortisol-binding globulin (CBG) and
activates cytochrome P450 3A4 CYP3A4, resulting in
accelerated metabolism of exogenous steroids [45].
Pituitary-directed drugs
This group of medications acts directly on corticotroph
adenomas to reduce ACTH secretion. Two currently
available classes of medications that act centrally are
dopamine type 2 receptor (D2R) agonists, and somato-
statin receptor ligands (SRL). Dose regimens and adverse
events are summarized in Table 1.
Dopamine D2 receptor agonists
About 80 % of corticotroph pituitary adenomas dem-
onstrate D2R expression [46, 47]. The two available
dopamine agonists are bromocriptine and cabergoline;
studies have shown variable short- and long-term ef-
fectiveness and adverse effects of bromocriptine, thus
limiting its use [14].
Small retrospective and open-label prospective studies
in patients with persistent CD after surgery demonstrate
biochemical response to cabergoline in up to 75 % of pa-
tients, though UFC normalization within 3–6 months
has only been reported in 25–40 % [48–51]. The “escape
phenomenon” is not uncommon, and reported in up to
one-third; long-term control of cortisol secretion over
12–24 months was demonstrated in 30–40 % of pa-
tients on cabergoline at a median dose of 2–3.5 mg/week
[49, 50]. Though it has been suggested that efficacy
improves with higher cabergoline doses [49–51], no con-
sistent dose-dependent reduction in cortisol levels was
seen in a short-term prospective study of 20 patients on a
median dose of 5 mg/week [52]. Tumor shrinkage is also
rare, reported in 20 % of cases [50]. As the data regarding
cabergoline’s efficacy is at present still limited, its use in
the treatment of CD remains off-label [14]. Cabergoline is
fairly well tolerated, and thus far, no significant association
has been found between its use for the treatment of
pituitary tumors and the development of clinically sig-
nificant cardiac valve disease [53].
Somatostatin receptor ligands (SRL)
Somatostatin inhibits ACTH synthesis and secretion.
Corticotroph adenomas commonly express somatostatin
receptors (SSTR), mainly type 2 (SSTR2) and 5 (SSTR5)
[54, 55]. However, hypercortisolism reduces expression
of SSTR2, and classical SRLs that act mainly on SSTR2
(octreotide and lanreotide) have not been shown to be
effective in patients with CD [56, 57]. Although de-
creasing cortisol levels may increase SSTR2 expression,
this phenomenon occurs at the mRNA level. No in-
crease of SSTR2 protein and receptor externalization
has been noted [58]. Further research has led to the de-
velopment of pasireotide, a multireceptor-targeted SRL
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with high binding activity to SSTR5, and also to SSTR2,
SSTR3 and SSTR1.
Pasireotide
In 2012, pasireotide became the first medical treatment
to be approved by the European Medicines Association
(EMA) and the United States Federal Drug Association
(FDA), for the treatment of CD after unsuccessful pituitary
surgery or when surgery is contraindicated. In a phase II,
open-label, single-arm, multicenter pilot study, 76 % of pa-
tients had a reduction in UFC and 17 % achieved complete
normalization when subcutaneous (sc) pasireotide was ad-
ministered at 600 μg twice a day for 15 days. Reductions
were also seen in serum cortisol and plasma ACTH levels
[59]. This was followed by a phase III, double-blind, ran-
domized clinical trial in which 162 patients were adminis-
tered 600 or 900 μg of pasireotide twice daily, with dose
escalations of 300 μg made after 3 months, depending on
UFC response. At 6 months, UFC decreased in the major-
ity; almost half had > 50 % reductions and 20 % achieved
normal UFC without dose escalation. Response was rapid,
with a median 50 % reduction of UFC in the first 2 months
of treatment. Open-label extension through 12 months
showed sustained UFC normalization in 13 % of patients
in the 600 μg group and 25 % in the 900 μg group. Of
note, patients with mild hypercortisolism at baseline had
higher UFC normalization rates than patients with severe
hypercortisolism [60]. Late-night salivary cortisol (LNSC)
was also measured in 93 patients, and normalized in 37
and 19 % of patients who had elevated baseline LNSC
levels, at 6 and 12 months, respectively. A moderate cor-
relation (r = 0.55) was found between LNSC and UFC
measurements [61]. Significant improvement in clinical
signs and symptoms was also seen at 12 months of treat-
ment [62]. Additional data from an international
expanded-access study also showed UFC normalization in
about 40 % of patients who remained on treatment at
48 weeks [63]. In a clinical practice setting study, 48 % of
patients with complete UFC normalization at 12 months
remained controlled at 24 months, suggesting the pos-
sibility of treatment escape in the remainder. Of note,
however, is that, despite this, clinical benefits, including
blood pressure control and weight reduction were sus-
tained [64]. Data from case reports and small case
series suggest that in a limited population, treatment
efficacy may extend beyond 5 years [65, 66]. More re-
cently, 60-month follow-up data demonstrate that ini-
tial reductions in UFC and clinical improvement were
maintained in patients who remained on treatment,
suggesting that pasireotide may be effective as a long-term
treatment in selected patients with CD [67]. Discontinu-
ation rate was, however, high due to unsatisfactory thera-
peutic effect (32.7 %), adverse events (22.2 %), consent
withdrawal (18.5 %) and administrative problems (9.9 %).
Tumor shrinkage has also been reported; about 9 and
44 % of patients on pasireotide 600 and 900 μg, res-
pectively, showed tumor size reduction at 12 months,
suggesting a dose-dependent effect [60]. More recently,
significant (>25 %) reductions in tumor volume and
even tumor disappearance has also been observed [68];
tumor shrinkage was also reported in corticotroph macro-
adenomas on de novo treatment with pasireotide [69].
Therefore, in addition to its use in patients with persistent
or recurrent CD after pituitary surgery, pasireotide may
also be useful as first line therapy in macroadenomas to
facilitate surgical resection.
With the exception of hyperglycemia incidence and
severity, the safety profile of pasireotide is similar to
other SRLs [60, 64, 70]. In the pivotal phase III study,
hyperglycemia-related adverse events were documented
in 73 %, the risk of which was higher in patients with
pre-existing diabetes or impaired glucose tolerance.
Hyperglycemia was observed soon after the initiation of
pasireotide, but glucose and glycated hemoglobin levels
stabilized after the initiation or escalation of glucose-
lowering therapy. At the end of the study, 48 % of
patients who did not have diabetes at baseline had
glycated hemoglobin ≥ 6.5 % [60]. Reduction in insulin
secretion and the incretin response have been demon-
strated in healthy volunteers receiving pasireotide [71].
Metformin and dipeptidyl peptidase 4 (DPP-4) inhibi-
tors are therefore generally recommended as first and
second line therapy, respectively for pasireotide-related
hyperglycemia [72, 73]. Glucagon-like peptide-1 (GLP-1)
agonists and insulin may also be required in cases of more
severe glucose intolerance [71, 72, 74].
An intramuscular long-acting-release (LAR) formula-
tion of pasireotide approved for the treatment of acro-
megaly is now being evaluated for use in CD. Pasireotide
LAR was previously reported to be effective in reducing
ACTH and tumor volume in a patient with Nelson’s
syndrome and aggressive corticotroph tumor growth
[75]. In a double-blind, randomized controlled phase III
trial of 150 patients with persistent, recurrent or de novo
CD, UFC normalization was observed in 40 % of patients
treated with pasireotide LAR 10 or 30 mg monthly for a
duration of 7 months. Median decrease in UFC was 48 %
[76]. Safety profile was similar to that of twice-daily sc
pasireotide. Hyperglycemia-related adverse events were
noted in 68 and 80 % of patients in the 10 and 30 mg
groups, respectively, which led to treatment discontinu-
ation in only 5 patients. As pasireotide LAR is adminis-
tered monthly, improved patient compliance is a potential
advantage over sc pasireotide.
Other regulators of the hypothalamus-pituitary-adrenal axis
Serotonin antagonists and gamma-amino butyric acid
(GABA) agonists are neuromodulatory drugs that have
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previously been studied in CD, but shown to have limited
efficacy, and serious adverse effects [4, 77, 78]. Results
from studies analyzing the nuclear receptor ligand,
peroxisome proliferator-activated receptor gamma (PPAR-
gamma) have also been inconsistent, mainly demonstrating
short-term disease control, high rates of treatment escape
and minimal clinical improvement [79–81].
Glucocorticoid receptor antagonists
Mifepristone
Mifepristone is a high-affinity, non-selective glucocortic-
oid receptor (GR) antagonist with ten and four times
greater affinity to the GR compared to cortisol and dexa-
methasone, respectively [82, 83]. GR antagonism results
in rapid control of the systemic effects of cortisol excess
in patients with CS. ACTH, and subsequently cortisol
levels increase due to a loss of negative feedback regula-
tion [84–86]. Such parameters are therefore, not useful
for monitoring treatment efficacy or disease activity. In-
stead, improvement in clinical and metabolic features
of CS should be used to evaluate treatment efficacy
[14, 87, 88].
Two studies have evaluated the efficacy and safety of
mifepristone. In the first retrospective study, 20 patients
with CS were treated with mifepristone; four had CD, 3
of whom had rapid improvement in clinical signs and
symptoms [89]. Following this was a large prospective
multicenter trial, Study of the Efficacy and Safety of Mife-
pristone in the Treatment of Endogenous Cushing’s
Syndrome (SEISMIC), which looked at the effects of
24 weeks of mifepristone (300–1200 mg/day) in 50
patients with CS, among whom 43 had CD [84]. In
patients with diabetes mellitus or glucose intolerance,
significant improvements in glucose profiles were ob-
served in 60 %. Decrease in body weight, waist circum-
ference and fat mass, and increases in insulin sensitivity
were observed in 87 % of patients. Post-hoc analysis also
demonstrated improvements in global clinical response
assessments (based on glucose, lipid and blood pressure
control, body composition, clinical appearance, strength,
psychiatric/cognitive symptoms and quality of life
parameters) in 88 % of patients at 24 weeks [90]. Of 27
patients who entered a long-term extension study (median
treatment duration 11.3 months), a dose-dependent ≥2-
fold increase in ACTH was observed in 72 %, which
returned to baseline after drug discontinuation. Tumor
progression was seen in four cases; three had macroade-
nomas and in one patient, follow-up MRI demonstrated a
microadenoma that was not previously detected at
diagnosis [91]. Recently, maintenance of weight loss
was demonstrated at 2 years follow-up [92]. Based on
results of the SEISMIC study, the FDA, in 2012, ap-
proved mifepristone for the treatment of patients with
endogenous CS who have failed surgery or are not
surgical candidates and have concomitant type 2 dia-
betes mellitus or glucose intolerance [10].
The lack of biochemical parameters for monitoring
treatment response to mifepristone is an important limi-
tation especially with regard to assessment for adrenal
insufficiency. Adrenal insufficiency was reported in 2 out
of 50 patients in the SEISMIC study; another 5 patients
were treated with dexamethasone for suspected adrenal
insufficiency. Due to mifepristone’s long half-life and
high affinity for the GR, supraphysiological doses of
dexamethasone (2–8 mg daily in this study) are needed
to overcome GR antagonism [22, 93]. High cortisol
levels also have the potential to overwhelm renal inacti-
vating enzyme 11 beta-hydroxysteroid dehydrogenase
type 2. Subsequent mineralocorticoid receptor activation
by excess cortisol results in hypertension, hypokalemia
and edema, which often respond well to potassium re-
placement and mineralocorticoid receptor blockade
with spironolactone [10, 84]. Additionally, due to its
anti-progestin activity, mifepristone is contraindicated
in pregnancy and in women with endometrial hyperplasia
or carcinoma, or unexplained vaginal bleeding [14, 89, 94].
A recent case report suggested, however, no endometrial
hyperplasia or proliferative changes in a patient with
prolonged exposure to ulipristal, another selective pro-
gesterone receptor modulator [95]. Caution is also
needed with concomitant use of CYP3A4 inhibitors
such as ketoconazole, which may increase mifepristone
levels, and drugs that increase QT interval, such as
pasireotide [94]. Other adverse events are summarized
in Table 1.
Combination drug therapy for Cushing’s disease
As highlighted above, no single drug has demonstrated
complete efficacy in the treatment of CD. Adverse
events are also not uncommonly encountered in patients
on medical therapy (Table 1). A strategy to increase
treatment efficacy, whilst reducing doses of individual
drugs and thereby minimizing adverse events, is to com-
bine drugs with additive, synergistic, and/or complemen-
tary mechanisms of action.
Combination of adrenal steroidogenesis inhibitors
Of 62 patients with CS (84 % CD) treated pre-operatively
with both ketoconazole (200–600 mg/day) and metyra-
pone (750–1000 mg/day), normalization of UFC was
observed in 45 %. Median duration of treatment was
4 months [30]. This combination is also used in the
treatment of severe CS when immediate surgery is contra-
indicated [10, 30, 33]. Additionally, use of 3 adrenal ste-
roidogenesis inhibitors, ketoconazole (400–1200 mg/day),
metyrapone (3.0–4.5 g/day) and mitotane (3.0–5.0 g/day),
resulted in rapid normalization of UFC and clinical im-
provement in 11 patients with severe ACTH-dependent
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CS (4 CD). Ketoconazole and metyrapone were success-
fully discontinued in 7 patients after 3.5 months; UFC
remained normal with mitotane monotherapy. There was,
however, a high rate of adverse events with this triple-
combination, with acute adrenal insufficiency being re-
ported in 36 % of patients, and liver enzyme elevation in
up to 82 % [96].
Cabergoline and ketoconazole
This treatment approach combines a pituitary-directed
drug with an adrenal steroidogenesis inhibitor, therefore
targeting both pituitary ACTH and adrenal cortisol syn-
thesis. In a small series, the addition of very low-dose ke-
toconazole (50–200 mg/day) to cabergoline (3.5 mg/week)
resulted in UFC normalization in six patients who had a
partial response to cabergoline [97]. Thereafter, in a pro-
spective study of 12 patients with persistent CD after
pituitary surgery, the addition of ketoconazole to cabergo-
line increased rates of UFC normalization from an initial
25 % with cabergoline alone (dose 2–3 mg/week), to
75 % when 200–400 mg/day of ketoconazole was
added. Amongst the six patients who benefitted from
combination therapy, subsequent cabergoline dose re-
ductions could be made in two patients [51]. Similar
findings were demonstrated in a subsequent prospective
analysis of 14 patients with persistent, recurrent or de
novo CD: combination therapy with cabergoline doses of
up to 3 mg/week and ketoconazole up to 600 mg/day re-
sulted in UFC normalization in 79 % of patients. Neither
drug was effective as monotherapy, nor did the choice of
starting treatment (cabergoline vs. ketoconazole) affect
outcomes [98]. Of note, though combination therapy
lowered late night salivary cortisol levels, they remained
elevated, indicating persistent abnormal diurnal variation.
Larger studies are needed to confirm these findings.
Pasireotide, cabergoline and ketoconazole
The combination of pasireotide, cabergoline and ketoco-
nazole was studied in a prospective open-label study of
17 patients with CD. Patients were placed on sc pasireo-
tide 100–250 μg 3 times/day at the start of the study. If
no disease control was achieved at 28 days, cabergoline
was added (0.5–1.5 mg every other day), and if UFC
remained elevated at 60 days, ketoconazole 200 mg 3
times/day was added. This step wise addition of first
cabergoline, and then ketoconazole to pasireotide, in-
creased UFC normalization rates from 29 to 53 to 88 %,
respectively at 80 days, with associated decreases in body
weight, waist circumference and blood pressure [99].
Quality of life did not change significantly in the short
term, but improved after 1 year of remission in three
patients who continued medical therapy [100]. A large
Fig. 1 Mechanism of action of novel medical treatments for Cushing’s disease. From left to right: R-roscovitine induces cell cycle arrest, tumor
shrinkage and reduction of ACTH synthesis and secretion. Exact mechanism of action is currently under study. Retinoic acid inhibits POMC expression,
decreasing ACTH synthesis and release. An additional novel treatment under evaluation is the selective, peptide melanocortin-2 receptor
(MC2R) antagonist that blocks ACTH action at the adrenal cortex. Osilodrostat is a steroidogenesis inhibitor that blocks the action of CYP11B1
and CYP11B2 (yellow X) with greater affinity than metyrapone. Levoketoconazole is a steroidogenesis inhibitor with greater potency than ketoconazole
in blocking CYP11B1, CYP21 and CYP17 during cortisol synthesis (red X). Osilodrostat and levoketoconazole are currently being studied in phase III
clinical trials
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prospective, phase II open-label pasireotide-cabergoline
study is currently under way [101].
Novel medical treatments for Cushing’s disease in
clinical trials
Osilodrostat (LCI699)
Osilodrostat is an oral inhibitor of 11 beta-hydroxylase
(CYP11B1) that blocks the hydroxylation of deoxycorti-
sol to cortisol, the final step in cortisol synthesis (Fig. 1).
Osilodrostat, first studied in patients with hyperaldoster-
onism, also inhibits the activity of aldosterone synthase
(CYP11B2), decreasing aldosterone synthesis [102]. In
these patients, a reduction in circulating cortisol levels
and adrenal insufficiency was observed, in addition to
the expected fall in aldosterone levels.
Osilodrostat shares a similar mechanism of action with
metyrapone. However, it is significantly more potent, hav-
ing a 3-fold higher affinity to 11 beta-hydroxylase than
metyrapone, as demonstrated in preclinical studies (in
vitro half maximal inhibitory concentration (IC50) of 7.5
nM vs 2.5 nM for metyrapone) [103]. In addition, its lon-
ger half-life allows twice daily oral administration, confer-
ring an advantage over metyrapone, which may require
administration up to 6 times daily [103, 104]. In a 10-
week, proof of concept study (LINC-1; NCT01331239),
osilodrostat demonstrated good efficacy, normalizing UFC
in 11 of 12 patients with CD. Mean ACTH, 11-
deoxycortisol and 11-deoxycorticosterone levels increased
during treatment but declined after discontinuation [103].
The extension phase study enrolled 4/12 of the original
cohort and an additional 15 new patients with CD with
UFC more than 1.5 × upper limit of normal (ULN). Pa-
tients received 4–10 mg per day as a starting dose depend-
ing on the degree of UFC elevation. Doses were then
adjusted every 2 weeks as needed to 10–60 mg/day until
UFC normalized. UFC normalized in 78.9 % of patients at
22 weeks [105]. Adverse reactions were well tolerated, the
most common of which were nausea, diarrhea and asthe-
nia. Adrenal insufficiency and/or glucocorticoid with-
drawal was reported in one-third of patients, highlighting
the potency of osilodrostat and the need for slow and
careful dose titration. Elevated testosterone levels, hirsut-
ism and acne were observed in 3 of 11 females (Table 1).
Importantly, no new safety signals were identified after
22 weeks of treatment. Interim analysis of the open-ended
extension study (LINC-2) points to sustained long-term
efficacy of osilodrostat. At 19 months, mean UFC and
0800 morning serum cortisol levels were within the nor-
mal range, an effect that had been observed since week 6.
Overall response rate was 93.8 % at week 22 and at month
19, with no treatment escape noted in any patients. Im-
provement was noted in weight and body mass index
(BMI) [106]. Based on these results, osilodrostat shows
promise as an alternative treatment in CD [104] and two
phase III studies (LINC-3 and LINC-4) are currently
underway.
Recently, the combination of osilodrostat and pasireo-
tide was evaluated in rats [107]. Acceptable safety and
efficacy was shown and lend interest to future testing of
this combination in clinical trials.
Levoketoconazole (COR-003)
Levoketoconazole is an investigational drug for CS that
acts similarly to its enantiomer, ketoconazole (2S,4R
and 2R,4S racemic mixture), but is hypothesized to pro-
vide better efficacy and safety. The (2S,4R) single en-
antiomer, levoketoconazole is 2 and 7 times more
potent than ketoconazole in inhibiting 21-hydroxylase
(CYP21) and 17 alpha-hydroxylase (CYP17), and 11
beta-hydroxylase (CYP11B1) steroidogenesis enzymes,
respectively (Fig. 1). A recent pre-clinical study also con-
firmed a significantly higher potency in enzyme inhibition
than its pure (2R, 4S) enantiomer. This theoretically leads
to lower doses, and fewer adverse events [104].
Experiments in an animal model showed greater po-
tency and efficacy in reducing serum corticosterone. In a
phase I study, when administered to healthy subjects,
levoketoconazole (400 mg/day) reduced serum cortisol
levels significantly by day 4, compared to placebo and
ketoconazole. The drug was well tolerated; headache,
back pain and nausea were the most frequently reported
adverse events [108]. Being 12 times less potent than ke-
toconazole in inhibiting CYP7A1, less interference with
bile acid synthesis and metabolite elimination, and there-
fore less hepatoxicity, is anticipated [108]. Reduction of
cholesterol and C- reactive protein have also been re-
ported in patients with type 2 diabetes mellitus after
short-term administration of levoketoconazole [109]. A
phase III single-arm, open-label trial (clinicaltrials.gov;
NCT01838551) is currently underway to evaluate the
efficacy, safety, tolerability and pharmacokinetics of levo-
ketoconazole in patients with CS [110].
R-Roscovitine
The cyclin-dependent kinase (CDK) and cyclin E inhibi-
tor R-roscovitine has been evaluated as potential therapy
for CD patients. R-roscovitine was first shown to be ef-
fective in reducing ACTH and serum corticosterone
levels in a mouse model. Further studies demonstrated
restraint of tumor growth after R-roscovitine treatment
in a mouse model with xenografted ACTH-secreting
pituitary tumor [111]. R-roscovitine induces corticotroph
tumor cell cycle arrest. Its mechanism of action is still
under study, and seems to be related to disruption of
cyclin E2F1 binding to proopiomelanocortin (POMC) gene
promoter and suppression of corticotroph transcription
factors, resulting in decreased ACTH expression (Fig. 1)
[112]. Currently, a phase II clinical trial (clinicaltrials.gov;
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NCT02160730) in human patients with CD is ongoing to
evaluate the efficacy and safety of R-roscovitine (Table 1).
Retinoic acid
Retinoic acid is a nuclear receptor ligand that was pro-
posed as a treatment for CD after it was shown to de-
crease ACTH secretion and corticotroph tumor growth
in vitro and in animal models, via inhibition of POMC
expression in corticotroph tumors (Fig. 1) [113]. The
first proof-of concept clinical study demonstrated ≥ 50 %
reduction in UFC in 5 of 7 patients after 6 months of
treatment with 10–80 mg/day of retinoic acid; UFC nor-
malized in three patients [114]. A recent open-label clinical
trial demonstrated that 20–80 mg/day of the 13-cis isomer
of retinoic acid, isotretinoin, resulted in UFC normalization
in 4 of 16 patients (25 %) at 12 months, with UFC reduc-
tions up to 52 % seen in the rest [115]. Adverse events,
though mild and reversible, were encountered in more
than 40 % of patients. Further randomized, double-blind,
clinical trials are needed to evaluate its efficacy in patients
with CD.
Medical treatments on the horizon
Epidermal growth factor receptor (EGFR) inhibitors
EGFR is expressed in the pituitary, but mainly in corti-
cotroph adenomas, and plays an important role in
tumorigenesis. Inhibition of ACTH secretion, reduction
in tumor size and clinical improvement were observed
in animal models treated with gefitinib, an EGFR tyro-
sine kinase inhibitor [116]. Recently, an additional
mechanism by which EGFR plays a role in the patho-
physiology of CD has been proposed, with potential
therapeutic applications [117]. The ubiquitin-specific
peptidase eight (USP8) gene was found to be mutated in
33–66 % of patients with CD [118]. Mutations clustered
around the 14-3-3 protein that enhances the catalytic ac-
tivity of USP8. As a result of these mutations, EGFR deu-
biquitination occurs, impairing its downregulation and
increasing its activity, signaling and ACTH secretion. Such
mutations have also been found to increase SSTR5 expres-
sion, and patients with these mutations may therefore,
show a better response to pasireotide. This has potential
therapeutic implications and warrants further
investigation.
Chimeric compounds
By working synergistically, chimeric compounds that
interact with both dopamine D2R and SSTRs have the
potential to be more potent than individual compounds
in controlling tumor growth and ACTH release [119, 120].
The chimeric compound BIM-23A760, which has high
affinity for SSTR2, D2R and to a lesser extent SSTR5, was
however, found to produce interfering metabolites that
compete with the activity of the drug itself, decreasing
its efficacy. Further development of second-generation
chimeric compounds is currently under way [121]. BIM-
065, which has potent bioactivity at both the SSTR2 and
D2R, has recently been developed. While it does have high
binding affinity to SSTR5, it has a lower bioactivity, than
pasireotide. Interestingly however, this compound was
shown to increase insulin sensitivity in normal rats [122].
Selective, peptide melanocortin-2 receptor antagonists
Recently, several peptides that act as ACTH antagonists
at the melanocortin-2 receptor (MC2R) have been dis-
covered. One particular compound, IRC-274, has been
observed in in vitro studies to inhibit ACTH production in
human embryonic kidney (HEK) 293 cells co-expressing
both MC2 and the melanocortin-2 receptor accessory pro-
tein (MRAP), and in two different rodent models, to re-
duce circulating corticosterone levels in a dose and
time-related manner [123, 124]. These observations
could lead to the development of a novel therapeutic
agent for the normalization of cortisol levels in CD
patients (Fig. 1).
Conclusions
Medical treatment for CD is an expanding and dynamic
field. Recent studies describing novel treatment strategies
have shown promising results, expanding the role for
medical therapy in the treatment of CD. New insights into
the pathophysiology of CD have led to new targets for
drug development aimed at decreasing ACTH secretion.
Currently available adrenal steroidogenesis inhibitors are
useful especially in the short-term control of cortisol ex-
cess but are associated with treatment escape, multiple ad-
verse effects and drug interactions. Pituitary-directed
drugs acting at the level of the corticotroph adenoma have
the potential advantage of tumor shrinkage. While data
for the use of cabergoline is limited, pasireotide and mife-
pristone have demonstrated good efficacy and tolerability.
Combination therapy is an additional strategy that aims
to increase treatment efficacy, whilst minimizing ad-
verse events. In particular, the combination of pasireo-
tide, cabergoline and ketoconazole has shown promise
and larger studies are awaited. Novel therapies such as
osilodrostat and levoketoconazole offer hope of in-
creased efficacy and R-roscovitine, retinoic acid, EGFR
inhibitors, second-generation chimeric compounds and
selective, peptide MC2R antagonists are emerging therapies
currently under evaluation. Ultimately, individualized treat-
ment is needed, depending on the severity of hypercortiso-
lemia, tumor size and comorbidities.
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